Phase II Study of Sunitinib (SU11248) in Patients With Kaposi's Sarcoma in East Africa.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Sunitinib (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- 05 May 2014 Biomarkers information updated
- 01 Jul 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
- 03 Jan 2013 Planned end date changed from 1 May 2007 to 1 Dec 2013 as reported by ClinicalTrials.gov.